BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 3, 2013
View Archived Issues
Epizyme presents novel epigenetic-targeted, small-molecule anticancer agents
Read More
Researchers present updated results for CART-19 cell therapy
Read More
Exploration of a key mechanistic pathway of antiapoptotic signaling in multiple myeloma
Read More
German and U.S. researchers design novel transgenic rat model for Huntington's disease
Read More
Novel agents for heart failure presented by German researchers
Read More
Novo Nordisk discloses new ligands binding to IL-21
Read More
New labeled NMDA receptor ligands patented by group in The Netherlands
Read More
Merz Pharma presents novel NMDA glycine B receptor antagonists
Read More
Novel monoclonal antibodies divulged by Antitope
Read More
Theravance synthesizes new series of neprilysin inhibitors
Read More
TRU-016 receives orphan medicinal product designation in Europe for CLL
Read More
Probuphine obtains FDA priority review designation for opioid dependence
Read More
Synergy Pharmaceuticals reports data from phase IIb/III plecanatide trial
Read More
Phase II SGI-110 trial begins in hepatocellular carcinoma
Read More
Photocure receives payment for Lumacan from Salix Pharmaceuticals
Read More
AbbVie launched as independent biopharmaceutical company
Read More
Phase IIb data presented for vaccine against enterotoxigenic bacteria
Read More
Small-molecule FADK inhibitor demonstrates efficacy for brain cancers
Read More
Results from a first-in-human phase I trial presented for AR-42
Read More
Kareus Therapeutics announces commencement of phase I trial for Alzheimer's disease candidate
Read More
Nexavar meets primary endpoint in RAI-refractory differentiated thyroid cancer
Read More
Clinical hold lifted for OncoMed's demcizumab
Read More
FDA deems complete Merck & Co's resubmission of NDA for ezetimibe/atorvastatin tablets
Read More
Relypsa reaches agreement with FDA for phase III trial of patiromer
Read More